Vir Biotechnology Inc. launched an initial public offering in October to keep progressing its immunological approaches to infectious diseases, including two clinical programs to treat hepatitis B virus (HBV) and prevent influenza A, and preclinical programs in HBV and HIV. Then the COVID-19 pandemic hit and the company’s stock price surged as it put forward multiple programs and entered into partnerships to prevent and treat the novel coronavirus.
[Sidebar#SC141896]






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
